Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
A variable rate of iron loading, reaching toxic levels in some patients, was seen in a series of non-transfused patients with beta thalassaemia intermedia or sideroblastic anaemia. The degree of anaemia was a poor guide to the risk of iron overload. However the extent of erythroid hyperplasia, judged by ferrokinetic studies or more simply by bone marrow aspiration, was useful in predicting both the rate of iron loading and the need for iron chelation therapy.
D000042:Absorption; D000284:Administration, Oral; D000367:Age Factors; D000756:Anemia, Sideroblastic / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D002614:Chelating Agents / Q000627:therapeutic use*; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D004906:Erythrocyte Count; D005293:Ferritins / Q000097:blood; D006720:Homozygote; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000378:metabolism* / Q000627:therapeutic use; D007504:Iron Radioisotopes; D012306:Risk; D013789:Thalassemia / Q000097:blood* / Q000188:drug therapy / Q000235:genetics
D002614:Chelating Agents; D007504:Iron Radioisotopes; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine